Monte Rosa Therapeutics, Inc. (GLUE)
NASDAQ: GLUE · Real-Time Price · USD
14.78
-0.99 (-6.28%)
At close: Aug 20, 2026, 4:00 PM EDT
14.78
0.00 (0.00%)
After-hours: Aug 20, 2026, 4:04 PM EDT
Monte Rosa Therapeutics Revenue
Monte Rosa Therapeutics had revenue of $8.97M in the quarter ending June 30, 2026, a decrease of -61.33%. This brings the company's revenue in the last twelve months to $28.73M, down -83.86% year-over-year. In the year 2025, Monte Rosa Therapeutics had annual revenue of $123.67M with 63.54% growth.
Revenue (ttm)
$28.73M
Revenue Growth
-83.86%
P/S Ratio
44.19
Revenue / Employee
$166,052
Employees
173
Market Cap
1.26B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 123.67M | 48.05M | 63.54% |
| Dec 31, 2024 | 75.62M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
GLUE News
- 13 days ago - Monte Rosa Therapeutics price target lowered to $28 from $35 at Guggenheim - TheFly
- 14 days ago - Monte Rosa Therapeutics reports Q2 revenue $8.97M, consensus $12.88M - TheFly
- 14 days ago - Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates - GlobeNewsWire
- 14 days ago - Monte Rosa Therapeutics Quarterly report: Q2 2026 - Filings
- 14 days ago - Monte Rosa Therapeutics Earnings release: Q2 2026 - Filings
- 14 days ago - Monte Rosa Therapeutics Slides: Corporate presentation - Filings
- 17 days ago - Monte Rosa Therapeutics price target lowered to $27 from $37 at Wedbush - TheFly
- 20 days ago - Monte Rosa, BioAge sink following Novo Nordisk’s ZEUS setback - TheFly